Phase II evaluation of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes
详细信息 查看全文
- 作者：Kunal C. Kadakia ; Charles L. Loprinzi ; Pamela J. Atherton…
- 关键词：SAMe ; S ; Adenosyl ; L ; methionine ; Hot flashes ; Quality of life ; Clinical trials
- 刊名：Supportive Care in Cancer
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：24
- 期：3
- 页码：1061-1069
- 全文大小：519 KB
- 参考文献：1.Freeman EW, Sammel MD, Sanders RJ (2014) Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause 21(9):924–932. doi:10.1097/GME.0000000000000196 PubMedCentral CrossRef PubMed
2.Couzi RJ, Helzlsouer KJ, Fetting JH (1995) Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol 13(11):2737–2744PubMed
3.Carpenter JS, Andrykowski MA, Cordova M, Cunningham L, Studts J, McGrath P, Kenady D, Sloan D, Munn R (1998) Hot flashes in postmenopausal women treated for breast carcinoma: prevalence, severity, correlates, management, and relation to quality of life. Cancer 82(9):1682–1691CrossRef PubMed
4.Loprinzi CL, Michalak JC, Quella SK, O’Fallon JR, Hatfield AK, Nelimark RA, Dose AM, Fischer T, Johnson C, Klatt NE et al (1994) Megestrol acetate for the prevention of hot flashes. N Engl J Med 331(6):347–352. doi:10.1056/NEJM199408113310602 CrossRef PubMed
5.(2012) The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 19 (3):257–271. doi:10.1097/gme.0b013e31824b970a
6.Loprinzi CL, Barton DL, Sloan JA, Novotny PJ, Dakhil SR, Verdirame JD, Knutson WH, Kelaghan J, Christensen B (2008) Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience. Menopause 15(4 Pt 1):655–660. doi:10.1097/gme.0b013e3181679150 CrossRef PubMed
7.Barton DL, LaVasseur BI, Sloan JA, Stawis AN, Flynn KA, Dyar M, Johnson DB, Atherton PJ, Diekmann B, Loprinzi CL (2010) Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol 28(20):3278–3283. doi:10.1200/JCO.2009.26.6379 PubMedCentral CrossRef PubMed
8.Freeman EW, Guthrie KA, Caan B, Sternfeld B, Cohen LS, Joffe H, Carpenter JS, Anderson GL, Larson JC, Ensrud KE, Reed SD, Newton KM, Sherman S, Sammel MD, LaCroix AZ (2011) Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. Jama 305(3):267–274. doi:10.1001/jama.2010.2016 PubMedCentral CrossRef PubMed
9.Stearns V, Beebe KL, Iyengar M, Dube E (2003) Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. Jama 289(21):2827–2834. doi:10.1001/jama.289.21.2827 CrossRef PubMed
10.Sun Z, Hao Y, Zhang M (2013) Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials. Gynecol Obstet Investig 75(4):255–262. doi:10.1159/000348564 CrossRef
11.Bordeleau L, Pritchard KI, Loprinzi CL, Ennis M, Jugovic O, Warr D, Haq R, Goodwin PJ (2010) Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol 28(35):5147–5152. doi:10.1200/JCO.2010.29.9230 CrossRef PubMed
12.Loprinzi CL, Dueck AC, Khoyratty BS, Barton DL, Jafar S, Rowland KM Jr, Atherton PJ, Marsa GW, Knutson WH, Bearden JD 3rd, Kottschade L, Fitch TR (2009) A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). Ann Oncol 20(3):542–549. doi:10.1093/annonc/mdn644 PubMedCentral CrossRef PubMed
13.Moraska AR, Atherton PJ, Szydlo DW, Barton DL, Stella PJ, Rowland KM Jr, Schaefer PL, Krook J, Bearden JD, Loprinzi CL (2010) Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB. J Support Oncol 8(3):128–132PubMedCentral PubMed
14.Barton DL, Loprinzi CL, Quella SK, Sloan JA, Veeder MH, Egner JR, Fidler P, Stella PJ, Swan DK, Vaught NL, Novotny P (1998) Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 16(2):495–500PubMed
15.Quella SK, Loprinzi CL, Barton DL, Knost JA, Sloan JA, LaVasseur BI, Swan D, Krupp KR, Miller KD, Novotny PJ (2000) Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group Trial. J Clin Oncol 18(5):1068–1074PubMed
16.Pockaj BA, Gallagher JG, Loprinzi CL, Stella PJ, Barton DL, Sloan JA, Lavasseur BI, Rao RM, Fitch TR, Rowland KM, Novotny PJ, Flynn PJ, Richelson E, Fauq AH (2006) Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol 24(18):2836–2841. doi:10.1200/JCO.2005.05.4296 CrossRef PubMed
17.Pruthi S, Qin R, Terstreip SA, Liu H, Loprinzi CL, Shah TR, Tucker KF, Dakhil SR, Bury MJ, Carolla RL, Steen PD, Vuky J, Barton DL (2012) A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North Central Cancer Treatment Group N08C7. Menopause 19(1):48–53. doi:10.1097/gme.0b013e318223b021 PubMedCentral CrossRef PubMed
18.Bottiglieri T (2002) S-Adenosyl-L-methionine (SAMe): from the bench to the bedside--molecular basis of a pleiotrophic molecule. Am J Clin Nutr 76(5):1151S–1157SPubMed
19.Hardy ML, Coulter I, Morton SC, Favreau J, Venuturupalli S, Chiappelli F, Rossi F, Orshansky G, Jungvig LK, Roth EA, Suttorp MJ, Shekelle P (2003) S-Adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease. Evid Rep Technol Assess (Summ) 64:1–3
20.Bottiglieri T, Laundy M, Martin R, Carney MW, Nissenbaum H, Toone BK, Johnson AL, Reynolds EH (1984) S-Adenosylmethionine influences monoamine metabolism. Lancet 2(8396):224CrossRef PubMed
21.Otero-Losada ME, Rubio MC (1989) Acute changes in 5-HT metabolism after S-adenosyl-L-methionine administration. Gen Pharmacol 20(4):403–406CrossRef PubMed
22.Bethea CL, Lu NZ, Gundlah C, Streicher JM (2002) Diverse actions of ovarian steroids in the serotonin neural system. Front Neuroendocrinol 23(1):41–100. doi:10.1006/frne.2001.0225 CrossRef PubMed
23.Moses-Kolko EL, Berga SL, Greer PJ, Smith G, Cidis Meltzer C, Drevets WC (2003) Widespread increases of cortical serotonin type 2A receptor availability after hormone therapy in euthymic postmenopausal women. Fertil Steril 80(3):554–559CrossRef PubMed
24.Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H (2001) Methodologic lessons learned from hot flash studies. J Clin Oncol 19(23):4280–4290PubMed
25.Shams T, Firwana B, Habib F, Alshahrani A, Alnouh B, Murad MH, Ferwana M (2014) SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. J Gen Intern Med 29(1):204–213. doi:10.1007/s11606-013-2535-9 PubMedCentral CrossRef PubMed
26.Drewe J, Bucher KA, Zahner C (2015) A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients. Springerplus 4:65. doi:10.1186/s40064-015-0808-y PubMedCentral CrossRef PubMed
27.Carpenter JS (2001) The Hot Flash Related Daily Interference Scale: a tool for assessing the impact of hot flashes on quality of life following breast cancer. J Pain Symptom Manag 22(6):979–989CrossRef
28.Curran S, Andrykowski M, Stadts J (1995) Short form of the profile of mood states (POMS-SF): psychometric information. Psychol Assess 7:80–83CrossRef
29.Wyrwich KW, Yu H (2011) Validation of POMS questionnaire in postmenopausal women. Qual Life Res 20(7):1111–1121. doi:10.1007/s11136-011-9846-2 CrossRef PubMed
30.Institute NC (2009) Common terminology criteria for adverse events v4.0 (NIH publication # 09–7473)
31.Loprinzi CL, Sloan J, Stearns V, Slack R, Iyengar M, Diekmann B, Kimmick G, Lovato J, Gordon P, Pandya K, Guttuso T Jr, Barton D, Novotny P (2009) Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol 27(17):2831–2837. doi:10.1200/JCO.2008.19.6253 PubMedCentral CrossRef PubMed
32.Williams AL, Girard C, Jui D, Sabina A, Katz DL (2005) S-Adenosylmethionine (SAMe) as treatment for depression: a systematic review. Clin Invest Med 28(3):132–139PubMed
33.Barton DL, Loprinzi CL, Atherton P, Raymond J, Shanafelt T, Hines S, Palmieri F, Rummans T, Adjei AA, Sloan J (2007) Phase II evaluation of desipramine for the treatment of hot flashes. Support Cancer Ther 4(4):219–224. doi:10.3816/SCT.2007.n.018 CrossRef PubMed
34.Pancheri P, Scapicchio P, Chiaie RD (2002) A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. Int J Neuropsychopharmacol 5(4):287–294. doi:10.1017/S1461145702003085 CrossRef PubMed
35.Bottiglieri T, Godfrey P, Flynn T, Carney MW, Toone BK, Reynolds EH (1990) Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry 53(12):1096–1098PubMedCentral CrossRef PubMed
36.Delle Chiaie R, Pancheri P, Scapicchio P (2002) Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. Am J Clin Nutr 76(5):1172S–1176SPubMed
37.Schmidt ME, Chang-Claude J, Vrieling A, Heinz J, Flesch-Janys D, Steindorf K (2012) Fatigue and quality of life in breast cancer survivors: temporal courses and long-term pattern. J Cancer Surviv 6(1):11–19. doi:10.1007/s11764-011-0197-3 CrossRef PubMed
38.Gutierrez S, Palacios I, Sanchez-Pernaute O, Hernandez P, Moreno J, Egido J, Herrero-Beaumont G (1997) SAMe restores the changes in the proliferation and in the synthesis of fibronectin and proteoglycans induced by tumour necrosis factor alpha on cultured rabbit synovial cells. Br J Rheumatol 36(1):27–31CrossRef PubMed
39.Di Benedetto P, Iona LG, Zidarich V (1993) Clinical evaluation of s-adenosyl-1-methionine versus transcutaneous electrical nerve stimulation in primary fibromyalgia. Curr Ther Res 53(2):222–229CrossRef
40.Jacobsen S, Danneskiold-Samsoe B, Andersen RB (1991) Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation. Scand J Rheumatol 20(4):294–302CrossRef PubMed
41.Bardia A, Novotny P, Sloan J, Barton D, Loprinzi C (2009) Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis. Menopause 16(3):477–483. doi:10.1097/gme.0b013e31818c91ca PubMedCentral CrossRef PubMed
42.Harris PF, Remington PL, Trentham-Dietz A, Allen CI, Newcomb PA (2002) Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manag 23(6):501–509CrossRef - 作者单位：Kunal C. Kadakia (1)
Charles L. Loprinzi (2)
Pamela J. Atherton (2)
Kelliann C. Fee-Schroeder (2)
Amit Sood (3)
Debra L. Barton (4)
1. Division of Hematology and Medical Oncology, University of Michigan, Ann Arbor, USA
2. Division of Medical Oncology, Mayo Clinic, Rochester, USA
3. Division of General Internal Medicine, Mayo Clinic, Rochester, USA
4. School of Nursing, University of Michigan, 400 N. Ingalls, Room 2153, Ann Arbor, MI, 48109, USA - 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Oncology
Nursing
Nursing Management and Research
Pain Medicine
Rehabilitation Medicine - 出版者：Springer Berlin / Heidelberg
- ISSN：1433-7339
文摘
Purpose Hot flashes are a significant source of symptom burden that negatively impacts quality of life (QOL). For women who have contraindications to, or are unwilling to consider, estrogens or antidepressants for bothersome hot flashes, there are limited effective pharmacologic or complementary and alternative medicines.